Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Galvanize Therapeutics Early Stage, Non-Small Cell Lung Cancer, Treat and Resect Study

NCT04732520 is registered in ClinicalTrials.gov with Galvanize Therapeutics, Inc. as lead sponsor.

NCT NCT04732520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04732520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Galvanize Therapeutics Early Stage, Non-Small Cell Lung Cancer, Treat and Resect Study
Lead sponsor
Galvanize Therapeutics, Inc.
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2021
Completion date
February 13, 2024
Enrollment
47 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer